A Phase 3 interventional study of Orforglipron and Placebo in Overweight, Prediabetic State and Prehypertension, sponsored by Eli Lilly and Company. Recruiting at 180 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Obesity, Abdominal with a site in United States — 7 open to participants now, 10 under way, 1 of them phase 3. Obesity, Abdominal · United States.
Among the 57 studies in Obesity, Abdominal with a site in United States, this one is the 4th largest by planned enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 3, and was the 56th registered.
295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.
Browse Obesity, Abdominal studies →7 of the 57 studies in Obesity, Abdominal with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 50–80
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–80 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–55 · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 40–65 · Women only · Healthy volunteers
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Obesity, Abdominal studies recruiting now, 3 (12%) set no upper age limit and 21 (81%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 5 · Phase 4 5
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,001 is above the median of 58 across 235 interventional studies indexed under Obesity, Abdominal.
Median enrollment 40 across the 53 interventional studies, 39 across the 4 observational. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 1 study filed under Obesity, Abdominal — fewer than ten, so there is no comparison to draw.
3 of the studies in Obesity, Abdominal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04532814Mayo ClinicExercise-stimulated Muscle Glucose Uptake in Upper Body Obesity | 2026-12-31 |
| NCT07869472University of VirginiaPost-exercise Blood Pressure With Inorganic Nitrate | 2027-01-01 |
| NCT05147909University of Texas Southwestern Medical CenterImpact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Obesity, Abdominal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.
This study's planned enrollment of 2,001 is above the median of 58 across 235 interventional studies indexed under Obesity, Abdominal.
Browse Obesity, Abdominal studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Obesity, Abdominal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive orforglipron orally
Drug: Orforglipron
Participants will receive orforglipron orally followed by placebo orally
Drug: Orforglipron · Drug: Placebo
Participants will receive placebo orally followed by orforglipron orally
Drug: Orforglipron · Drug: Placebo
Administered orally
Also known as: LY3502970
Administered orally
Time to Onset of Obesity Related Complications or Class 1 Obesity
Obesity related complications defined as type 2 diabetes, hypertension, or dyslipidemia; Class 1 obesity defined as body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or an equivalent region-specific threshold
Time frame: Baseline to Week 104
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 104
Time to Onset of Waist-to-Height Ratio ≥0.6
Time frame: Baseline to Week 104
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 104
Time to Onset of Class 1 Obesity
Time frame: Baseline to Week 104
Time to First Occurrence of Composite Endpoint of Type 2 Diabetes, Hypertension, Dyslipidemia
Time frame: Baseline to Week 104
Time to Onset of Type 2 Diabetes
Time frame: Baseline to Week 104
Percent Change from Baseline in Total Fat Mass
Time frame: Baseline, Week 104
Change from Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 104
Change from Baseline in Glycated Hemoglobin (HbA1c)
Time frame: Baseline, Week 104
Percent Change from Baseline in Triglycerides
Time frame: Baseline, Week 104
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Score
Time frame: Baseline, Week 104
Pharmacokinetics (PK): Steady-State Area Under the Curve (AUC) of Orforglipron
Time frame: Week 4, 12, 24, 52, and 76
Showing the first 100 of 180 sites across 12 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Aug 2026 (actual). Primary completion is estimated for Aug 2029, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron